Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company focused on central nervous system (CNS) diseases, has announced its plans to report third quarter 2024 financial and business results on November 4, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will lead the call, presenting the results and answering questions. Investors can access the live webcast through the company's Investor Relations website. Pre-registration is available for participants, who will receive a personalized dial-in number and conference code.
Supernus Pharmaceuticals (Nasdaq: SUPN), un'azienda biofarmaceutica focalizzata sulle malattie del sistema nervoso centrale (SNC), ha annunciato i suoi piani per riportare i risultati finanziari e aziendali del terzo trimestre 2024 il 4 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una call e webcast alle 16:30 ET lo stesso giorno.
Jack Khattar, Presidente e CEO, e Tim Dec, Vicepresidente Senior e CFO, guideranno la call, presentando i risultati e rispondendo alle domande. Gli investitori possono accedere al webcast dal vivo tramite il sito web delle Relazioni con gli Investitori dell'azienda. È disponibile la pre-registrazione per i partecipanti, che riceveranno un numero di accesso personalizzato e un codice conferenza.
Supernus Pharmaceuticals (Nasdaq: SUPN), una compañía biofarmacéutica centrada en enfermedades del sistema nervioso central (SNC), ha anunciado sus planes para reportar los resultados financieros y de negocios del tercer trimestre de 2024 el 4 de noviembre de 2024, después del cierre del mercado. La compañía llevará a cabo una llamada y webcast a las 4:30 p.m. ET el mismo día.
Jack Khattar, Presidente y CEO, y Tim Dec, Vicepresidente Senior y CFO, liderarán la llamada, presentando los resultados y respondiendo preguntas. Los inversores pueden acceder a la transmisión en vivo a través del sitio web de Relaciones con Inversores de la empresa. Se encuentra disponible la preinscripción para los participantes, quienes recibirán un número de llamada personalizado y un código de conferencia.
Supernus Pharmaceuticals(Nasdaq: SUPN)은 중추 신경계(CNS) 질병에 집중하는 바이오제약 회사로, 2024년 3분기 재무 및 사업 결과를 2024년 11월 4일에, 시장 마감 후 발표할 예정이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜 및 웹캐스트를 진행할 것입니다.
Jack Khattar 사장 겸 CEO와 Tim Dec 선임 부사장 겸 CFO가 전화를 주도하여 결과를 발표하고 질문에 답변할 것입니다. 투자자는 회사의 투자자 관계 웹사이트를 통해 생중계 웹캐스트에 접속할 수 있습니다. 참여자를 위한 사전 등록이 가능하며, 개인화된 다이얼인 번호와 컨퍼런스 코드를 받을 수 있습니다.
Supernus Pharmaceuticals (Nasdaq: SUPN), une société biopharmaceutique axée sur les maladies du système nerveux central (SNC), a annoncé ses plans pour présenter les résultats financiers et commerciaux du troisième trimestre 2024 le 4 novembre 2024, après la fermeture du marché. L'entreprise organisera une conférence téléphonique et un webcast à 16h30 ET le même jour.
Jack Khattar, Président et CEO, et Tim Dec, Vice-Président Senior et CFO, dirigeront l'appel, présentant les résultats et répondant aux questions. Les investisseurs peuvent accéder au webcast en direct via le site Web des relations investisseurs de l'entreprise. Une préinscription est disponible pour les participants, qui recevront un numéro d'appel personnalisé et un code de conférence.
Supernus Pharmaceuticals (Nasdaq: SUPN), ein biopharmazeutisches Unternehmen, das sich auf Erkrankungen des zentralen Nervensystems (ZNS) konzentriert, hat angekündigt, dass es am 4. November 2024, nach Börsenschluss, die finanziellen und geschäftlichen Ergebnisse des dritten Quartals 2024 bekannt geben wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten.
Jack Khattar, Präsident und CEO, und Tim Dec, Senior Vice President und CFO, werden die Konferenz leiten, die Ergebnisse präsentieren und Fragen beantworten. Investoren können über die Investoren-Relations-Website des Unternehmens auf den Live-Webcast zugreifen. Eine Vorregistrierung für Teilnehmer ist möglich, die dann eine persönliche Einwahlnummer und einen Konferenzcode erhalten.
- None.
- None.
ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2024 after the market closes on Monday, November 4, 2024.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the third quarter 2024 financial and business results on Monday, November 4, 2024 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/Investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/Investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
FAQ
When will Supernus Pharmaceuticals (SUPN) report its Q3 2024 financial results?
What time is Supernus Pharmaceuticals' (SUPN) Q3 2024 earnings call scheduled for?
Who will be hosting Supernus Pharmaceuticals' (SUPN) Q3 2024 earnings call?
How can investors access Supernus Pharmaceuticals' (SUPN) Q3 2024 earnings call?
